Where does Wakunaga Pharmaceutical Co., Ltd. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Wakunaga Pharmaceutical Co., Ltd. ranks #30,586 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Wakunaga Pharmaceutical Co., Ltd. hold?

Wakunaga Pharmaceutical Co., Ltd. holds 9 US utility patents granted between 2015 and 2025, spanning 11 technology areas.

What is Wakunaga Pharmaceutical Co., Ltd.'s Innovation Score?

Wakunaga Pharmaceutical Co., Ltd. has an Innovation Score of 30.5 out of 100 (35th percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

Is Wakunaga Pharmaceutical Co., Ltd.'s patent grant rate increasing or decreasing?

Wakunaga Pharmaceutical Co., Ltd.'s recent grant velocity is -25% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for Wakunaga Pharmaceutical Co., Ltd.'s patents?

Wakunaga Pharmaceutical Co., Ltd.'s patents average 10.7 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Wakunaga Pharmaceutical Co., Ltd. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Wakunaga Pharmaceutical Co., Ltd.

Q: What technology areas does Wakunaga Pharmaceutical Co., Ltd. focus on?

Wakunaga Pharmaceutical Co., Ltd.'s top technology area is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations) with 8 patents. Grants appear in 11 CPC subclasses total.

USPTO PatentsView assignee record - 9 granted patents across 11 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Wakunaga ranks #30,586 of 49,997 tracked US assignees by granted-patent volume, with 9 patents across 11 technology areas.

#30,586
of 49,997 US assignees by volume: 35th percentile
by Innovation Score (30.5/100): 10.7
avg claims per patent: -25%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R30586 · Foreign Corporation #30,586 · 9 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-FOCUS · INNOV-THIN · CLAIMS-PAR · TYPE-FRNCORP · VEL-DOWN · BOOK-FULL

GRANTS-MICRO 9 grants
MID-PACK #30,586/49,997
PHOTO-FINISH Voyant Photonics
CPC-FOCUS A61P · 11 areas
INNOV-THIN 30.5/100
CLAIMS-PAR 10.7 claims/avg
TYPE-FRNCORP Foreign Corp
VEL-DOWN -25% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Voyant Photonics, Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Qualcomm Incorporated · highest

85
Wakunaga Pharmaceuti… · this assignee

31
3D Lighting… · lowest

7

What this shows Wakunaga's Innovation Score is 30.5/100 (35th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Where Wakunaga's grants concentrate

Wakunaga Pharmaceutical Co., Ltd. is a focused PatentsView assignee: 11 CPC subclasses with 88.9% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2015 (2 grants) versus a trough of 1 in 2020. By volume, Wakunaga sits between Voyant Photonics, Inc. and WB Development Company LLC.

Wakunaga's three-year grant acceleration

Wakunaga Pharmaceutical Co., Ltd. shows 2 grants in 2022–2024 against only 3 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Voyant Photonics

9
Vringo Infrastruc…

9
Vueron Technology

9
Vulcan Shanghai

9
Walbro Engine Man…

9
Water IO

9
Ways Technical

9
WB Development

9
Wakunaga Pharmace… ◀

9

What this shows Wakunaga holds 9 patents at rank #30,554, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Wakunaga

By rank, the assignees closest to #30,554 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Wakunaga's primary technology class.

Wakunaga's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

31 35th percentile higher than 35% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Wakunaga Pharmaceutical Co., Ltd. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	2	22.2%
2019	2	22.2%
2020	1	11.1%
2022	1	11.1%
2023	1	11.1%
2025partial year	2	22.2%

Which technologies does Wakunaga Pharmaceutical Co., Ltd. patent most?

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 8

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 6

A23L - Foods, Foodstuffs OR Non-alcoholic Beverages, NOT Otherwise Provided FOR; Preparation OR Treatment Thereof 4

C07D - Heterocyclic Compounds 3

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 1

C12Q - Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Microbiological OR Enzymological Processes 1

C07K - Peptides 1

Y02A - Technologies FOR Adaptation TO Climate Change 1

Y02P - Climate Change Mitigation Technologies IN THE Production OR Processing OF Goods 1

A23V - Indexing Scheme Relating TO Foods, Foodstuffs OR Non-alcoholic Beverages AND Lactic OR Propionic Acid Bacteria Used IN Foodstuffs OR Food Preparation 1

C07C - Acyclic OR Carbocyclic Compounds 1

Top 11 of 11 technology areas

Where it ranks

Overall rank by patents

#30,586

of 49,997 tracked assignees

Innovation Score

30.5 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

What to do with this data

Wakunaga Pharmaceutical Co., Ltd.'s patent record in context - here's where to go next.

Wakunaga Pharmaceutical Co., Ltd.'s lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 88.9% of its portfolio - see every assignee active in that class. Explore A61P
Ranked #30,586 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Wakunaga Pharmaceutical Co., Ltd. against Voyant Photonics, Inc., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 30.5/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.